

Cover Story
By Matthew Bin Han Ong
When two women—a patient advocate and a scientist—embarked on a mission to collect “normal” breast tissue for comparative purposes, colleagues in oncology dismissed their idea as wild.
In Brief


Drugs & Targets
Trending Stories
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
- How George Tidmarsh crossed the FDA-industry Rubicon
- Cancer centers adapt to life without site visits as NIH changes CCSG review
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA
- How GLP-1RA drugs are reshaping patient physiology and the future of oncology
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval















